Shanghai Junshi Biosciences Management

Management Kriterienprüfungen 3/4

Shanghai Junshi Biosciences' CEO ist Cong Li , ernannt in Nov 2021, hat eine Amtszeit von 2.58 Jahren. Die jährliche Gesamtvergütung beträgt CN¥4.22M , bestehend aus 100% Gehalt und 0% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.013% der Aktien des Unternehmens, im Wert von HK$3.38M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.8 Jahre bzw. 6 Jahre.

Wichtige Informationen

Cong Li

Geschäftsführender

CN¥4.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	100.0%
Amtszeit als Geschäftsführer	2.6yrs
Eigentum des Geschäftsführers	0.01%
Durchschnittliche Amtszeit des Managements	2.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Cong Li im Vergleich zu den Einnahmen von Shanghai Junshi Biosciences verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-CN¥2b
Dec 31 2023	CN¥4m	CN¥4m	-CN¥2b
Sep 30 2023	n/a	n/a	-CN¥2b
Jun 30 2023	n/a	n/a	-CN¥2b
Mar 31 2023	n/a	n/a	-CN¥3b
Dec 31 2022	CN¥4m	CN¥4m	-CN¥2b

Vergütung im Vergleich zum Markt: CongDie Gesamtvergütung ($USD582.16K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD452.48K).

Entschädigung vs. Einkommen: CongDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Cong Li (60 yo)

2.6yrs

Amtszeit

CN¥4,224,000

Vergütung

Mr. Cong Li has been Co-Chief Executive Officer and Executive Director at Shanghai Junshi Biosciences Co., Ltd. since November 2, 2021 and served as Non-Executive Director since December 22, 2016 until Nov...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jun Xiong	Executive Chairman	9.3yrs	CN¥8.50m	13.09% CN¥ 3.4b
Cong Li	Co-CEO & Executive Director	2.6yrs	CN¥4.22m	0.013% CN¥ 3.4m
Jianjun Zou	GM, CEO & Executive Director	less than a year	CN¥5.86m	keine Daten
Ning Li	Executive Vice-Chairman of the Board	6yrs	CN¥9.93m	0.0051% CN¥ 1.3m
Baohong Xu	Financial Director	3.6yrs	CN¥2.73m	0.00071% CN¥ 186.2k
Zhuobing Zhang	Deputy GM & Executive Director	no data	CN¥8.13m	0.88% CN¥ 230.3m
Sheng Yao	Senior VP & Executive Director	no data	CN¥8.01m	keine Daten
Gang Wang	Deputy GM	4.8yrs	CN¥1.32m	0.0010% CN¥ 267.5k
Xin Li	Executive Director	less than a year	keine Daten	0.0096% CN¥ 2.5m
Lu Yuan	Assistant to GM & Chief of Internal Audit Department	3.6yrs	keine Daten	keine Daten
Qian Wei	Chief Commercial Officer	2.9yrs	keine Daten	keine Daten
Patricia Keegan	Chief Medical Officer	no data	keine Daten	keine Daten

2.8yrs

Durchschnittliche Betriebszugehörigkeit

51.5yo

Durchschnittliches Alter

Erfahrenes Management: 1877Das Führungsteam des Unternehmens gilt als erfahren (2.8 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Jun Xiong	Executive Chairman	9.3yrs	CN¥8.50m	13.09% CN¥ 3.4b
Cong Li	Co-CEO & Executive Director	7.5yrs	CN¥4.22m	0.013% CN¥ 3.4m
Jianjun Zou	GM, CEO & Executive Director	2yrs	CN¥5.86m	keine Daten
Ning Li	Executive Vice-Chairman of the Board	6yrs	CN¥9.93m	0.0051% CN¥ 1.3m
Zhuobing Zhang	Deputy GM & Executive Director	7.5yrs	CN¥8.13m	0.88% CN¥ 230.3m
Sheng Yao	Senior VP & Executive Director	7.5yrs	CN¥8.01m	keine Daten
Gang Wang	Deputy GM	less than a year	CN¥1.32m	0.0010% CN¥ 267.5k
Xin Li	Executive Director	less than a year	keine Daten	0.0096% CN¥ 2.5m
Yu Wu	Chairman of the Board of Supervisors	6yrs	keine Daten	keine Daten
Yi Tang	Non-Executive Director	9.1yrs	keine Daten	0.74% CN¥ 193.9m
Chun Zhang	Independent Non-Executive Director	4yrs	CN¥200.00k	keine Daten
Xiaoyuan Feng	Independent Non-Executive Director	2.5yrs	CN¥200.00k	keine Daten

6.0yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 1877Die Vorstandsmitglieder gelten als erfahren (6 Jahre durchschnittliche Amtszeit).

Shanghai Junshi Biosciences Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Recent updates

Shanghai Junshi Biosciences Co., Ltd. Receives Drug Registration Certificate Issued by the National Medical Products Administration

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 21, 2024

First quarter 2024 earnings released

Shanghai Junshi Biosciences Co., Ltd. Receives Notice from the Drug Office, Department of Health, the Government of the Hong Kong Special Administration Region

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection

Shanghai Junshi Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: CN¥2.32 loss per share (vs CN¥2.60 loss in FY 2022)

Full year 2023 earnings released: CN¥2.28 loss per share (vs CN¥2.60 loss in FY 2022)

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer

Shanghai Junshi Biosciences Co., Ltd. and Topalliance Biosciences Inc Appoints Li Ning as Vice Chairman of the Third Session of the Board

Shanghai Junshi Biosciences Co., Ltd. Announces Publication of Results from Toripalimab, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Shanghai Junshi Biosciences Co., Ltd. Announces New Indications of TUOYI and MINDEWEI Included in New Edition of National Reimbursement Drug List

Shanghai Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia's TGA

Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

New minor risk - Profitability

Third quarter 2023 earnings released: CN¥0.42 loss per share (vs CN¥0.75 loss in 3Q 2022)

Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Directors Appointments

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab for the First-Line Treatment of Melanoma Met Primary Endpoint

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Notice of Approval for Clinical Trial

Shanghai Junshi Biosciences Co., Ltd. Announces Resignation of Wu Hai as Non-Executive Director

Second quarter 2023 earnings released: CN¥0.46 loss per share (vs CN¥0.56 loss in 2Q 2022)

Shanghai Junshi Biosciences Co., Ltd. (SEHK:1877) announces an Equity Buyback for CNY 60 million worth of its shares.

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of the Supplemental New Drug Application for Toripalimab as the First-Linetreatment of Advanced RCC

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces JS207 Injection Received the Acceptance Notice For the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 30, 2023

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Supplemental New Drug Application for Toripalimab in Combination with Chemotherapy for Treatment of Advanced Triple - Negative Breast Cancer

Shanghai Junshi Biosciences Co., Ltd. Announces Phase III Clinical Study of Toripalimab in Combination with Chemotherapy for the First-Line Treatment of ES-SCLC Met Primary Endpoint

First quarter 2023 earnings released: CN¥0.55 loss per share (vs CN¥0.44 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02

Shanghai Junshi Biosciences Co., Ltd. Announces JS401 Injection Receival the Acceptance Notice for The Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2022

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of NDA for VV116 in China

Now 26% undervalued

Shanghai Junshi Biosciences Co., Ltd, Shanghai Juntop Biosciences Co., Ltd. and Vigonvita Life Sciences Co., Ltd. Announce Progress of the Clinical Studies of VV116

Shanghai Junshi Biosciences Co., Ltd. Receives Acceptance Notice for the Investigational New Drug Application

Shanghai Junshi Biosciences Co., Ltd Announces Nejm Publication of Results of Phase 3 Study of Vv116 Versus Paxlovid for Adults At High Risk for Progression to Severe Covid-19

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Shanghai Junshi Biosciences Co., Ltd. Announces Board Changes

Shanghai Junshi Biosciences Co., Ltd. Announces Acceptance of Marketing Authorization Application of Toripalimab

Shanghai Junshi Biosciences Co., Ltd Submits Marketing Authorization Application for Toripalimab to the UK Medicines and Healthcare Products Regulatory Agency

Shanghai Junshi Biosciences Co., Ltd. Announces Receiving the Notice of Approval for Supplemental Drug Application Issued by the National Medical Products Administration

No longer forecast to breakeven

Shanghai Junshi Biosciences Co., Ltd. Announces Submission of A Marketing Authorization Application to the European Medicines Agency for Toripalimab

Shanghai Junshi Biosciences Co., Ltd. Receives the Notice of Approval for Clinical Trial Issued by the National Medical Products Administration

Third quarter 2022 earnings released: CN¥0.75 loss per share (vs CN¥0.50 loss in 3Q 2021)

Shanghai Junshi Biosciences Co., Ltd. to Report Nine Months, 2022 Results on Oct 28, 2022

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

Shanghai Junshi Biosciences Co., Ltd Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: CN¥0.57 loss per share (vs CN¥0.37 loss in 2Q 2021)

Suzhou Junjing Biomedical Technology Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

Shanghai Junshi Biosciences Co., Ltd. to Report Q2, 2022 Results on Aug 30, 2022

Shanghai Junshi Biosciences Co., Ltd. Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma

Now 21% undervalued after recent price drop

Shanghai Junshi Biosciences Co., Ltd. Receives Notice of Approval for Clinical Trial Issued by National Medical Products Administration

Forecast to breakeven in 2024

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Shanghai Junshi Biosciences Co., Ltd. and Risen (Suzhou) Pharma Tech Co., Ltd. Announces FDA Approval of Investigational New Drug Application for JS105

Shanghai Junshi Biosciences Co., Ltd. Appoints Zou Jianjun as Executive Director

Shanghai Junshi Biosciences Co., Ltd., Annual General Meeting, Jun 29, 2022